Phase II Study of JS212 Combination Therapy for Advanced Lung Cancer Including NSCLC and ES-SCLC

What this Trial Is About

Researchers are evaluating the combination therapy of JS212 with other drugs in patients with advanced lung cancer, including non-small cell lung cancer NSCLC and extensive-stage small cell lung cancer ES-SCLC. This Phase II, open-label, multicenter study aims to assess the response rate, safety, tolerability, and early effectiveness of JS212 combined with JS207, Toripalimab, or JS213, with or without chemotherapy. It focuses on patients who have either failed previous treatments or have not yet received systemic anti-tumor therapy. The study consists of two parts a safety introduction phase and a clinical expansion phase. JS212 is given by intravenous infusion on Day 1 of each 21-day cycle in all treatment groups. Depending on the group, JS212 is combined with JS207, Toripalimab, or JS213, also given intravenously on Day 1 of each 21-day cycle. Chemotherapy may be added based on safety evaluations. The study includes multiple cohorts to explore different combinations and their safety profiles. Participants will undergo evaluations including tumor response assessments according to standard criteria, safety monitoring, and measurement of drug levels in the blood. Researchers will track outcomes such as objective response rate, progression-free survival, duration of response, disease control rate, overall survival, and adverse events for up to six years. Laboratory tests and immunogenicity assessments will also be conducted. The study lasts several years with ongoing safety and efficacy follow-up.

A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung Cancer